I called the ward my 76yo mother had been on for a week to see if she was being discharged
The nurse said 'she's departed'
'fgfr,!#@**?????' says I
'sorry, she's discharged'
The nurse said 'she's departed'
'fgfr,!#@**?????' says I
'sorry, she's discharged'
A question from Reddit that I'll answer here:
"What's the most unhinged thing a doctor has said to you with a straight face?"
"What's the most unhinged thing a doctor has said to you with a straight face?"
August 6, 2026 at 9:04 AM
I called the ward my 76yo mother had been on for a week to see if she was being discharged
The nurse said 'she's departed'
'fgfr,!#@**?????' says I
'sorry, she's discharged'
The nurse said 'she's departed'
'fgfr,!#@**?????' says I
'sorry, she's discharged'
Great work by PhD student Patricio Ferrer Murguia. His paper reporting the twist mutant in Nematostella is out: doi.org/10.1242/dev....
twist is required to form secondary tentacles, via localized FGFR and mTOR signaling. Later, mutants form stunning epithelial neoplasia with tentacle identity.
twist is required to form secondary tentacles, via localized FGFR and mTOR signaling. Later, mutants form stunning epithelial neoplasia with tentacle identity.
July 22, 2026 at 8:55 PM
Great work by PhD student Patricio Ferrer Murguia. His paper reporting the twist mutant in Nematostella is out: doi.org/10.1242/dev....
twist is required to form secondary tentacles, via localized FGFR and mTOR signaling. Later, mutants form stunning epithelial neoplasia with tentacle identity.
twist is required to form secondary tentacles, via localized FGFR and mTOR signaling. Later, mutants form stunning epithelial neoplasia with tentacle identity.
I'm very happy to share the first paper out of my postdoc, now available at @devbiol.bsky.social
This story started as a collaboration during my PhD, where we aimed to uncover the transcriptional responses to FGF in a complex and branching system: the salivary gland.
doi.org/10.1016/j.yd...
(1/4)
This story started as a collaboration during my PhD, where we aimed to uncover the transcriptional responses to FGF in a complex and branching system: the salivary gland.
doi.org/10.1016/j.yd...
(1/4)
April 29, 2026 at 5:25 PM
I'm very happy to share the first paper out of my postdoc, now available at @devbiol.bsky.social
This story started as a collaboration during my PhD, where we aimed to uncover the transcriptional responses to FGF in a complex and branching system: the salivary gland.
doi.org/10.1016/j.yd...
(1/4)
This story started as a collaboration during my PhD, where we aimed to uncover the transcriptional responses to FGF in a complex and branching system: the salivary gland.
doi.org/10.1016/j.yd...
(1/4)
June 1, 2025 at 3:07 PM
August 8, 2026 at 8:03 PM
within the group a cell is either FGF-expressing or FGFR-expressing. The cells where FGFR is expressed will become primitive endoderm (PE), while the cells expressing the ligand FGF will become epiblast (EPI). The PE cells’ FGFR receives FGF ligand from other cells (4/n)
January 24, 2026 at 10:51 PM
within the group a cell is either FGF-expressing or FGFR-expressing. The cells where FGFR is expressed will become primitive endoderm (PE), while the cells expressing the ligand FGF will become epiblast (EPI). The PE cells’ FGFR receives FGF ligand from other cells (4/n)
Did you know that scientists in our @cruk-si.bsky.social Drug Discovery Unit were the brains behind Rucaparib (PARP inhibitor) and Erdafitinib (FGFR inhibitor, both now clinically approved cancer medicines. Read more about our ground breaking drug discovery science here www.ncl.ac.uk/cancer/our-r...
November 19, 2024 at 1:21 PM
Did you know that scientists in our @cruk-si.bsky.social Drug Discovery Unit were the brains behind Rucaparib (PARP inhibitor) and Erdafitinib (FGFR inhibitor, both now clinically approved cancer medicines. Read more about our ground breaking drug discovery science here www.ncl.ac.uk/cancer/our-r...
Our Blue Skies repost of April and Eric's preprint, on behalf of the www.bandolab.org, Ligon Lab, David Jones, and collaborators, focused on FGFR-alterations in pediatric gliomas. #TeamScience #PedBrainTumors @broadinstitute.bsky.social #DanaFarber @dkfz.bsky.social
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas
Alterations in Fibroblast growth factor receptor (FGFR)-family proteins frequently occur as oncogenes in many cancers, including a subset of pediatric gliomas. Here, we performed a genomic analysis of...
www.biorxiv.org
November 18, 2024 at 3:38 AM
Our Blue Skies repost of April and Eric's preprint, on behalf of the www.bandolab.org, Ligon Lab, David Jones, and collaborators, focused on FGFR-alterations in pediatric gliomas. #TeamScience #PedBrainTumors @broadinstitute.bsky.social #DanaFarber @dkfz.bsky.social
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Tremendous talk by Dr. Kailey Oppat @winshipatemory.bsky.social on #FGFR and #IDH interaction with #immune signatures in #cholangiocarcinoma via collab w #carisls @cholangiocarcinoma.bsky.social annual meeting!
April 10, 2025 at 11:15 PM
Tremendous talk by Dr. Kailey Oppat @winshipatemory.bsky.social on #FGFR and #IDH interaction with #immune signatures in #cholangiocarcinoma via collab w #carisls @cholangiocarcinoma.bsky.social annual meeting!
Harding, M. J., & Nechiporuk, A. V. (2012). Fgfr-Ras-MAPK signaling is required for apical constriction via apical positioning of Rho-associated kinase during mechanosensory organ formation. Development, 139(17), 3130–3135. #EpithelialMechanics
buff.ly/UERtwWl
buff.ly/UERtwWl
December 3, 2025 at 8:01 AM
Harding, M. J., & Nechiporuk, A. V. (2012). Fgfr-Ras-MAPK signaling is required for apical constriction via apical positioning of Rho-associated kinase during mechanosensory organ formation. Development, 139(17), 3130–3135. #EpithelialMechanics
buff.ly/UERtwWl
buff.ly/UERtwWl
📌 FGFR inhibitors (like pemigatinib, erdafitinib, infigratinib) have transformed care for FGFR-altered cholangiocarcinoma.
🚨 A new study analysis led to a model characterizing the biology of acquired resistance 🔍
#AnnalsOfOncology
#Onco404 #Cholangiocarcinoma #DrugResistance #Oncology #oncsky
🚨 A new study analysis led to a model characterizing the biology of acquired resistance 🔍
#AnnalsOfOncology
#Onco404 #Cholangiocarcinoma #DrugResistance #Oncology #oncsky
March 18, 2025 at 3:33 PM
📌 FGFR inhibitors (like pemigatinib, erdafitinib, infigratinib) have transformed care for FGFR-altered cholangiocarcinoma.
🚨 A new study analysis led to a model characterizing the biology of acquired resistance 🔍
#AnnalsOfOncology
#Onco404 #Cholangiocarcinoma #DrugResistance #Oncology #oncsky
🚨 A new study analysis led to a model characterizing the biology of acquired resistance 🔍
#AnnalsOfOncology
#Onco404 #Cholangiocarcinoma #DrugResistance #Oncology #oncsky
Survival and Safety of Tinengotinib in Advanced FGFR inhibitor R/R CCA - Arndt Vogel
@arndtvogel.bsky.social
oncodaily.com/voices/tinen...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@arndtvogel.bsky.social
oncodaily.com/voices/tinen...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Arndt Vogel: Survival and Safety of Tinengotinib in Advanced FGFR inhibitor R/R CCA - OncoDaily
Arndt Vogel: Survival and Safety of Tinengotinib in Advanced FGFR inhibitor R/R CCA / Arndt Vogel, cancer, ESMO, ESMO 2025, ESMO2025, ESMO25, OncoDaily,
oncodaily.com
October 21, 2025 at 10:40 PM
Survival and Safety of Tinengotinib in Advanced FGFR inhibitor R/R CCA - Arndt Vogel
@arndtvogel.bsky.social
oncodaily.com/voices/tinen...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@arndtvogel.bsky.social
oncodaily.com/voices/tinen...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Excited to share our paper reporting significance of FGFR-alterations across pediatric gliomas. Congratulations April Apfelbaum and Eric Morin and to everyone across our labs and collaborators. Thank you to the foundations and patients/ families who made this happen. www.bandolab.org
rdcu.be/eyHcG
rdcu.be/eyHcG
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas
Nature Communications - A subset of pediatric gliomas harbour alterations in fibroblast growth factor receptor (FGFR)-family proteins. Here, the authors characterise the genomic landscape of 11,635...
rdcu.be
July 31, 2025 at 1:34 PM
Excited to share our paper reporting significance of FGFR-alterations across pediatric gliomas. Congratulations April Apfelbaum and Eric Morin and to everyone across our labs and collaborators. Thank you to the foundations and patients/ families who made this happen. www.bandolab.org
rdcu.be/eyHcG
rdcu.be/eyHcG
Ebright et al. in the Sellers Lab at Broad Institute map genetic interactions in pancreatic cancer, revealing that combined KRAS and FGFR inhibition is synergistic and cytotoxic, overcoming resistance and enhancing treatment efficacy.
bioRxiv (Evolutionary Biology)
www.biorxiv.org
September 28, 2026 at 12:22 AM
Ebright et al. in the Sellers Lab at Broad Institute map genetic interactions in pancreatic cancer, revealing that combined KRAS and FGFR inhibition is synergistic and cytotoxic, overcoming resistance and enhancing treatment efficacy.
Spotlight: Kaushik and Ladher @earlab.bsky.social discuss recent work from Nita et al. (rupress.org/jcb/article/...), describing how FGFR2 localization at primary #cilia affects FGFR signaling and highlighting the role of the cilium in a disease-related context. rupress.org/jcb/article/...
June 12, 2025 at 6:22 PM
Spotlight: Kaushik and Ladher @earlab.bsky.social discuss recent work from Nita et al. (rupress.org/jcb/article/...), describing how FGFR2 localization at primary #cilia affects FGFR signaling and highlighting the role of the cilium in a disease-related context. rupress.org/jcb/article/...
Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer https://www.biorxiv.org/content/10.64898/2026.09.24.754062v1
September 25, 2026 at 11:48 AM
Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer https://www.biorxiv.org/content/10.64898/2026.09.24.754062v1
Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer https://www.biorxiv.org/content/10.64898/2026.09.24.754062v1
September 25, 2026 at 11:48 AM
Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer https://www.biorxiv.org/content/10.64898/2026.09.24.754062v1
New research in @natmed.nature.com by @danafarber.bsky.social’s Dr. Suzanne George and Dr. Bradley Bernstein reveals the clinical activity of FGFR inhibition in SDH-deficient GIST. ➡️bit.ly/497QeW8 @broadinstitute.org
May 27, 2026 at 3:30 PM
New research in @natmed.nature.com by @danafarber.bsky.social’s Dr. Suzanne George and Dr. Bradley Bernstein reveals the clinical activity of FGFR inhibition in SDH-deficient GIST. ➡️bit.ly/497QeW8 @broadinstitute.org
Lenvatinib (VEGFR1-3 FGFR, PDGFR, RET protooncogene KI) induced nephrotic syndrome
from what I can see about 6 weeks to months to resolve after stopping
would people rechallenge with it? Lower dose or best to avoid?
#Askrenal #OncoNephrology
cc @kdjhaveri.bsky.social @aisha-shaikh.bsky.social
from what I can see about 6 weeks to months to resolve after stopping
would people rechallenge with it? Lower dose or best to avoid?
#Askrenal #OncoNephrology
cc @kdjhaveri.bsky.social @aisha-shaikh.bsky.social
December 19, 2024 at 4:07 PM
Lenvatinib (VEGFR1-3 FGFR, PDGFR, RET protooncogene KI) induced nephrotic syndrome
from what I can see about 6 weeks to months to resolve after stopping
would people rechallenge with it? Lower dose or best to avoid?
#Askrenal #OncoNephrology
cc @kdjhaveri.bsky.social @aisha-shaikh.bsky.social
from what I can see about 6 weeks to months to resolve after stopping
would people rechallenge with it? Lower dose or best to avoid?
#Askrenal #OncoNephrology
cc @kdjhaveri.bsky.social @aisha-shaikh.bsky.social
Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer #SingleCell 🧪🧬🖥️
https://www.biorxiv.org/content/10.64898/2026.09.24.754062v1
https://www.biorxiv.org/content/10.64898/2026.09.24.754062v1
September 25, 2026 at 1:00 PM
Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer #SingleCell 🧪🧬🖥️
https://www.biorxiv.org/content/10.64898/2026.09.24.754062v1
https://www.biorxiv.org/content/10.64898/2026.09.24.754062v1
Ah, the FGFR that I rarely think about because it isn't in the nervous system.
February 9, 2025 at 6:06 AM
Ah, the FGFR that I rarely think about because it isn't in the nervous system.
Axonal regeneration the C. elegans depends on DLK-1. Dendritic regeneration is independent of DLK-1. High throughput screen identifies a role for FGFR signaling in dendrite regeneration. Anindya Ghosh-Roy, NBRC. #M2T22025 IIT-Jodhpur
February 17, 2025 at 5:15 AM
Axonal regeneration the C. elegans depends on DLK-1. Dendritic regeneration is independent of DLK-1. High throughput screen identifies a role for FGFR signaling in dendrite regeneration. Anindya Ghosh-Roy, NBRC. #M2T22025 IIT-Jodhpur
Targeting mutant FGFR1 in high-risk neuroblastoma could reverse treatment failures, offering hope through FGFR-directed therapies in resistant cases.
by Werr L, Boland J (...) Fischer M et 44 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/189152
by Werr L, Boland J (...) Fischer M et 44 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/189152
February 21, 2026 at 2:47 AM
Targeting mutant FGFR1 in high-risk neuroblastoma could reverse treatment failures, offering hope through FGFR-directed therapies in resistant cases.
by Werr L, Boland J (...) Fischer M et 44 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/189152
by Werr L, Boland J (...) Fischer M et 44 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/189152
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer https://www.biorxiv.org/content/10.64898/2026.02.16.706009v1
February 18, 2026 at 4:49 AM
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer https://www.biorxiv.org/content/10.64898/2026.02.16.706009v1